'Dose sparing' flu vaccine could boost productivity and vaccine availability

Credit: National Cancer Institute

The currently licensed seasonal trivalent influenza vaccines contain 15 micrograms of viral hemagglutinin protein per strain for adults, and up to 60 micrograms for elderly individuals; however, due to recent shortages, reducing these doses would be highly desirable. A recent study has found that significant dose sparing is possible with the use of whole virion vaccines and aluminium adjuvants, without compromising safety.

Whole virion vaccines contain whole virus, not just hemagglutinin as in most human flu vaccines. Adjuvants are added to help create a stronger immune response in the patient's body.

"Based on our results, a new, reduced dose seasonal vaccine is being licensed in the European Union member state in Hungary, which will impact production capacities and ultimately, availability to patients," wrote the authors of the British Journal of Clinical Pharmacology study.

Explore further

Adjuvants improve immune response to H7N9 flu vaccine

More information: British Journal of Clinical Pharmacology (2017). DOI: 10.1111/bcp.13289
Provided by Wiley
Citation: 'Dose sparing' flu vaccine could boost productivity and vaccine availability (2017, April 5) retrieved 21 April 2021 from https://medicalxpress.com/news/2017-04-dose-flu-vaccine-boost-productivity.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments